is defined by recurrent major depressive episodes punctuated by at least one lifetime hypomanic episode, never a full manic or mixed manic episode. The depressive pole dominates the illness in time, distress, and disability, which is why patients are routinely misdiagnosed with unipolar and treated with antidepressant monotherapy — a sequence that can destabilize the course. DSM-5-TR places Bipolar II disorder in the Bipolar and Related Disorders chapter alongside Bipolar I, cyclothymia, and substance-induced presentations, and explicitly rejects the older view that Bipolar II is a milder form of Bipolar I. Suicide risk is high and the long-term burden of subsyndromal depression is substantial. The clinical task is to detect retrospectively in someone presenting with depression, and to build a treatment plan around mood stabilization rather than antidepressants alone.
Bipolar II is less common than major depressive disorder but more common than Bipolar I, and it is heavily under-recognized in primary care and outpatient psychiatry. Population studies converge on a lifetime prevalence near 0.4-1.1% and a 12-month prevalence around 0.3-0.8%, although prevalence rises substantially when diagnostic methods explicitly probe for past hypomania.1-2
Prevalence and onset
- Lifetime prevalence approximately 0.4-1.1% in cross-national epidemiologic surveys, with 12-month prevalence near 0.3-0.8%.1-2
- Mean age of onset is in the early-to-mid 20s, typically slightly later than Bipolar I but earlier than unipolar depression.2-3
- The first lifetime mood episode is depressive in roughly two-thirds to three-quarters of cases, which delays correct diagnosis by an average of 5-10 years.3-4
Sex distribution
- Roughly equal sex ratio overall, in contrast with unipolar depression's female predominance.2
- Women have a higher rate of , , and depressive predominance; men have higher rates of comorbid substance use disorder.3,5
Comorbidity
- Lifetime comorbid anxiety disorder in approximately 75% of patients, most often , , and social anxiety.2-3
- Lifetime comorbid substance use disorder in approximately 35-60%, with alcohol most common.2-3
- Comorbid , ADHD, and eating disorders are over-represented relative to the general population.3,5
- Suicide attempts occur in roughly 25-35% of patients across the lifetime, with completed-suicide rates comparable to Bipolar I.3,6
Risk factors
- Family history of bipolar disorder is the strongest single risk factor, with first-degree relative risk approximately 5-10 times the population baseline.3,5
- Childhood adversity, particularly emotional and sexual abuse, is associated with earlier onset and worse course.3,7
- Postpartum period is a high-risk window for first hypomanic or depressive episodes in vulnerable women.3,8
Bipolar II shares much of its neurobiology with Bipolar I, although the two disorders are not interchangeable on imaging, genetics, or treatment response. The dominant model is one of dysregulated affective circuits — limbic hyperreactivity coupled with weakened prefrontal top-down control — superimposed on high heritability and gene-by-environment interactions.3,9
Neurobiology
- Functional imaging shows hyperactivation to emotional stimuli with reduced ventrolateral and dorsolateral prefrontal modulation, consistent with impaired emotion regulation.9-10
- Structural studies report subtle reductions in hippocampal and prefrontal gray-matter volume that progress with episode burden.9-10
- Disruption of the and the is reported in both depressive and hypomanic states.9
- Monoamine systems are involved but no single neurotransmitter abnormality explains the syndrome; dopaminergic upregulation is implicated in hypomania and serotonergic-noradrenergic dysfunction in the depressive pole.3,11
Genetics
- Heritability estimates from twin studies are approximately 60-85% for the bipolar spectrum overall.3,12
- Genome-wide association studies implicate , ANK3, ODZ4, and several other loci shared with and major depression, supporting a polygenic architecture.12-13
- Bipolar II appears to have a stronger familial loading for Bipolar II specifically (rather than Bipolar I), suggesting partial genetic distinctness.3,5
Environmental and psychosocial factors
- Sleep disruption, including jet lag and shift work, can precipitate hypomanic episodes in vulnerable individuals.3,14
- Stressful life events, particularly losses and goal-attainment events, precede mood episodes more often than chance would predict.3
- Substance use, especially stimulants, cannabis, and alcohol, both precipitates and worsens episodes.3,15
Integrative model
- Current models frame Bipolar II as a polygenic vulnerability to affective instability, expressed through dysregulated reward and threat circuits, and triggered by sleep disruption, substance use, and life stress.3,9
DSM-5-TR requires the lifetime occurrence of at least one hypomanic episode and at least one , with no history of a manic or mixed manic episode.16 The asymmetry between the two poles is intentional: a single past hypomania, even brief, in a patient currently depressed reframes the diagnosis and the treatment plan.
Core requirements
- At least one lifetime hypomanic episode meeting full criteria, and at least one lifetime major depressive episode meeting full criteria, in the absence of any past manic or mixed manic episode.16
- The hypomanic and depressive episodes are not better explained by , schizophrenia, , , or another psychotic disorder.16
- Mood symptoms cause clinically significant distress or functional impairment, most often driven by the depressive episodes or by the unpredictability of cycling rather than by hypomania itself.16
Hypomanic episode criteria
- Distinct period of abnormally and persistently elevated, expansive, or irritable mood and persistently increased activity or energy, lasting at least four consecutive days, present most of the day nearly every day.16
- At least three of the following (four if mood is only irritable): inflated self-esteem or grandiosity; decreased need for sleep; pressured speech; flight of ideas or racing thoughts; distractibility; increased goal-directed activity or ; excessive involvement in activities with high potential for painful consequences such as spending sprees, sexual indiscretions, or impulsive business decisions.16
- The change is uncharacteristic of the person's usual functioning and is observable by others.16
- The episode is not severe enough to cause marked impairment, does not require hospitalization, and lacks psychotic features — any of which would convert the diagnosis to Bipolar I.16
- Symptoms are not attributable to a substance or another medical condition. A hypomanic episode that emerges during antidepressant treatment and persists at full syndromal level beyond the physiological effect of that treatment is sufficient evidence of bipolarity in DSM-5-TR.16
DIG FAST
Distractibility, Indiscretion, Grandiosity, Flight of ideas, Activity increase, Sleep deficit, Talkativeness — the seven hypomanic/manic symptom domains.
Major depressive episode criteria
- Five or more of the nine symptoms during the same two-week period, with at least one being depressed mood or : depressed mood; markedly diminished interest or pleasure; significant weight or appetite change; insomnia or hypersomnia; psychomotor agitation or retardation; fatigue; feelings of worthlessness or excessive guilt; impaired concentration; recurrent thoughts of death or suicidal ideation.16
- Symptoms cause clinically significant distress or impairment and are not attributable to a substance or another medical condition.16
SIG E CAPS
Sleep, Interest, Guilt, Energy, Concentration, Appetite, , Suicidality — paired with depressed mood, the depressive-episode checklist.
Specifiers
- Current or most recent episode: hypomanic or depressed.16
- Severity (for current depressive episode): mild, moderate, severe.16
- With anxious distress, with mixed features, with rapid cycling, with melancholic features, with atypical features, with mood-congruent or mood-incongruent psychotic features (depressive only), with catatonia, with peripartum onset, with seasonal pattern.16
- Course specifiers: in partial remission, in full remission.16
A hypomanic episode with three or more concurrent depressive symptoms qualifies for the with mixed features specifier and is associated with worse course and higher suicide risk.16-17
ICD-11 considerations
- ICD-11 retains a Bipolar type II category in the mood disorders chapter, with broadly similar criteria but a four-day minimum that some clinicians and researchers argue is too restrictive for shorter, well-characterized hypomanic episodes.18
- ICD-11 separates mixed episodes from with mixed features and recognizes a single mixed episode as Bipolar I rather than Bipolar II, mirroring DSM-5-TR.18
Bipolar II is fundamentally a depressive illness with intermittent hypomania. Patients spend roughly half of follow-up time symptomatic, with depressive symptoms outnumbering hypomanic symptoms by approximately 35-to-1 in longitudinal data.19
Depressive presentation
- Atypical features are common: leaden paralysis, hyperphagia, hypersomnia, mood reactivity, and rejection sensitivity.3,17
- , early-morning awakening, and diurnal mood variation can also occur.3
- Subsyndromal depressive symptoms persist between episodes in the majority of patients and account for most of the functional disability.19
Hypomanic presentation
- Hypomania is often experienced as a return to normal or as a productive period, which is why patients underreport it unless asked specifically and concretely.3,17
- Common observable features: decreased need for sleep without daytime fatigue, increased talkativeness, expansive plans, increased spending, social disinhibition, and irritability that surprises family.3,17
- Mixed features — depressive symptoms during hypomania, or hypomanic symptoms during depression — are common, often presenting as agitated, dysphoric hypomania with racing thoughts, irritability, and suicidal ideation.17,20
Course
- Chronic and recurrent in the majority of patients, with frequent depressive recurrences and less frequent hypomanic episodes.3,19
- Rapid cycling (four or more episodes in 12 months) occurs in 15-30% of patients and is more common in women.3,17
- Conversion to Bipolar I (a first manic episode) occurs in approximately 5-15% of Bipolar II patients over long-term follow-up.3,21
Red flags suggesting bipolarity in a depressed patient:
- Onset of depression before age 25.17,22
- Highly recurrent depressive episodes (three or more lifetime).17,22
- Family history of bipolar disorder, completed suicide, or psychiatric hospitalization.17,22
- Atypical depressive features (hypersomnia, hyperphagia, leaden paralysis).17,22
- Postpartum depression or .8,17
- , particularly with non-response or worsening on antidepressant monotherapy.17,22
- Antidepressant-induced hypomania, mood lability, agitation, or insomnia.17,22
- Brief, recurrent depressive episodes (less than two weeks).17,22
FIND ME
Family history, Insomnia (decreased need), Need for novelty, Distractibility, Mood lability, Energetic — bedside cues that should trigger a hypomania probe in a depressed patient.
CLINICAL SCENARIO: A 28-year-old woman presents with her fourth depressive episode in six years. She tells you the SSRI her last clinician prescribed gave her a week of feeling great — sleeping three hours, redecorating her apartment, picking up a new business idea — and then she crashed harder than before. That history reframes her diagnosis from recurrent unipolar depression to Bipolar II with antidepressant-associated hypomania, and changes the next prescription.16-17
The differential is structured around two questions: is this bipolar at all, and if so is it Bipolar I or Bipolar II? Most diagnostic errors run in one direction — calling Bipolar II unipolar depression — but the reverse error of overcalling brief mood lability as hypomania is also clinically harmful.
Major depressive disorder
- The discriminating feature is a documented past hypomanic episode meeting full duration and symptom criteria, not transient mood shifts.16,22
- Atypical features, early onset, high recurrence, and family history raise pretest probability of bipolarity but do not diagnose it on their own.17,22
Bipolar I disorder
- A single lifetime manic episode (seven days or more, severe enough to impair functioning, require hospitalization, or include psychosis) reclassifies the patient as Bipolar I, regardless of how many hypomanic episodes preceded it.16
Cyclothymic disorder
- Two or more years of fluctuating subsyndromal hypomanic and depressive symptoms that never meet full episode criteria.16
- If a full hypomanic or depressive episode emerges later, the diagnosis converts to Bipolar II (or Bipolar I, if manic).16
Substance- or medication-induced bipolar disorder
- Mood symptoms occurring exclusively in the context of intoxication, withdrawal, or recent medication initiation, with full resolution after the offending agent is removed.16
- Stimulants, corticosteroids, levodopa, and certain antibiotics are common precipitants.3,16
Bipolar disorder due to another medical condition:
- Multiple sclerosis, traumatic brain injury, stroke (particularly right-hemisphere), neurosyphilis, HIV, lupus, hyperthyroidism, and Cushing syndrome can produce mood elevation.3,23
Borderline personality disorder
- Affective instability is the major source of confusion. Borderline mood shifts are typically brief (hours), reactive to interpersonal events, and not accompanied by decreased need for sleep, sustained increased goal-directed activity, or pressured speech across days.24
- The two diagnoses also co-occur, and meeting criteria for one does not exclude the other.24
ADHD:
- Distractibility, talkativeness, and increased activity are chronic and pervasive in ADHD rather than episodic, and ADHD lacks decreased need for sleep, grandiosity, or distinct mood elevation.3,25
Anxiety and trauma-related disorders
- Hyperarousal, insomnia, and irritability in PTSD and GAD can mimic hypomanic features but lack expansive mood, increased goal-directed activity, and decreased need for sleep.3
Schizoaffective disorder and primary psychotic disorders
- Mood symptoms in Bipolar II by definition lack psychotic features during hypomania; the presence of psychosis points away from Bipolar II toward Bipolar I, schizoaffective disorder, or a primary psychotic disorder.16
The single most important assessment task in suspected Bipolar II is a structured probe for past hypomania, ideally with a corroborating informant. Self-report alone misses approximately 30-50% of past hypomanic episodes.26
History essentials
- Longitudinal mood timeline going back to adolescence, mapping depressive episodes, periods of unusual mood elevation, and any periods of decreased need for sleep without daytime fatigue.3,17
- Concrete probes rather than abstract questions: ask about the longest period of feeling unusually good, energetic, productive, or irritable; the least amount of sleep tolerated without fatigue; periods of unusual spending, increased sexual activity, or impulsive decisions.17
- Family psychiatric history including bipolar disorder, completed suicide, hospitalization, and response in relatives.3,5
- Medication and substance history, with particular attention to antidepressant-associated mood elevation, irritability, or insomnia.17,22
- Suicide risk assessment at every visit, including past attempts, current ideation, plan, intent, access to lethal means, and protective factors.6,27
Informant interview
- A spouse, parent, or close friend can identify hypomanic episodes the patient experienced as normal or productive.17,26
- Asking the informant to describe the patient at their most active or expansive often elicits criterion-level features the patient did not volunteer.17
Physical examination and laboratory
- Targeted physical exam to screen for thyroid disease, neurologic disorders, and substance use stigmata.3
- Baseline labs before mood-stabilizer initiation: TSH, comprehensive metabolic panel, complete blood count, fasting glucose and lipids, urine drug screen, pregnancy test in women of childbearing potential, and ECG when clinically indicated or before specific agents.28-29
- Lithium-specific baseline: TSH, BUN, creatinine, electrolytes, calcium, urinalysis, pregnancy test, weight, and ECG in patients over 40 or with cardiac risk.28-29
Lithium has eight baseline checks to remember — TFTs, BUN, creatinine, electrolytes (with calcium), pregnancy test, weight, ECG, and urinalysis.
Validated rating scales
- (MDQ): 13-item self-report screen for lifetime hypomania/; sensitivity around 0.7 and specificity around 0.9 in psychiatric outpatients, lower in primary care.30
- (HCL-32): 32-item self-report with higher sensitivity than the MDQ for Bipolar II specifically.31
- (BSDS): narrative-format screen sensitive to softer bipolar presentations.32
- (YMRS): 11-item clinician-rated severity scale for current manic/hypomanic symptoms; not a diagnostic instrument.33
- (HAM-D) and (MADRS) for depressive severity tracking.34-35
- for primary-care depression screening; useful for monitoring but does not screen for hypomania.36
Imaging and tests not routinely indicated
- Neuroimaging is reserved for atypical presentations, focal neurologic findings, late-onset first episode, or rapid cognitive decline.3
- Routine EEG, genetic testing, and biomarker panels are not currently recommended for diagnosis.3
Initiating an antidepressant in a patient with undiagnosed Bipolar II can precipitate hypomanic , mixed features, rapid cycling, or accelerated suicidal ideation. Screen for past hypomania before prescribing an antidepressant for any depressed patient with red-flag features.17,22,37
Bipolar II treatment is anchored in mood stabilization across the lifespan, with the largest unmet need being effective and durable management of bipolar depression. The evidence base for Bipolar II is smaller than for Bipolar I, and most guidelines extrapolate from Bipolar I trials with caution.38-39
Pharmacotherapy
- For acute Bipolar II depression, evidence supports quetiapine monotherapy as first-line, with positive randomized trials specifically in Bipolar II.38-40
- Lurasidone has positive evidence in bipolar I depression and is commonly used in Bipolar II depression based on extrapolation; cariprazine has guideline support in bipolar depression.39,41
- Lithium is recommended as a maintenance agent with evidence for relapse prevention and reduction of suicide risk, and is often used despite a smaller acute-depression evidence base in Bipolar II than in Bipolar I.38-39,42
- Lamotrigine is recommended for maintenance, with stronger evidence for prevention of depressive recurrence than manic recurrence; titration must be slow to mitigate Stevens-Johnson syndrome risk.38-39,43
- Valproate is an option for maintenance and for hypomania with mixed features, although the Bipolar II evidence base is limited.38-39
- Antidepressant monotherapy is not recommended; if an antidepressant is used, it should be combined with a or atypical antipsychotic, and the patient monitored for hypomanic switching, mixed features, and rapid cycling.37-39
- () and bupropion are generally preferred over tricyclics and serotonin-norepinephrine reuptake inhibitors () when an antidepressant is used, because of lower switch risk; even so, switch risk is non-zero.37,39
- For acute hypomania, options include atypical antipsychotics (quetiapine, olanzapine, risperidone, aripiprazole), lithium, or valproate, with rapid taper of any contributing antidepressant.39
Lamotrigine requires slow titration (typically 25 mg daily for two weeks, then 50 mg daily for two weeks, then weekly increases) to reduce the risk of serious rash, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Doses of valproate and other enzyme inhibitors require lower lamotrigine doses; carbamazepine and other inducers require higher.43
Lithium has a narrow therapeutic window of 0.6-1.2 mEq/L for maintenance, with toxicity above 1.5 mEq/L. Check levels 5-7 days after each dose change, then every 3-6 months once stable, with TFTs and renal function at least annually.28,42
Psychotherapy
- Strong evidence supports adjunctive psychoeducation in reducing relapse rates, particularly for hypomanic and manic episodes, when added to pharmacotherapy.44-45
- adapted for bipolar disorder (CBT-BD) has evidence for reducing depressive symptoms and improving function as an adjunct to medication.44-45
- (IPSRT) targets sleep-wake regularity and social rhythm disruption, with evidence for relapse prevention.44,46
- Family-focused therapy (FFT) reduces relapse and improves medication adherence in patients living with high-expressed-emotion families.44,47
- Dialectical behavior therapy skills training is reasonable for patients with comorbid borderline personality disorder, emotion-regulation deficits, or recurrent self-harm.44
Neuromodulation
- () is highly effective for severe, treatment-resistant, or psychotic bipolar depression and for catatonia.48-49
- () has evidence in bipolar depression but with smaller effect sizes than in unipolar depression and inconsistent durability; switch risk appears low but is not zero.50
- and vagus nerve stimulation remain experimental or limited to specific treatment-resistant contexts.39
Adjunctive
- Sleep regularization, including consistent sleep-wake times, light exposure, and avoidance of shift work where possible, is a low-risk intervention with biological rationale.3,46
- Reduction or elimination of stimulants, alcohol, and cannabis, with referral for substance use treatment when indicated.3,15
- Suicide-risk reduction with means restriction (firearms, large medication supplies) is recommended at every visit when risk is elevated.6,27
- Thyroid optimization in patients on lithium with subclinical or overt hypothyroidism, given the relationship between thyroid status and mood.42
- Omega-3 fatty acids, N-acetylcysteine, and inositol have limited and inconsistent evidence; some experts recommend them as low-risk adjuncts, though high-quality evidence is lacking.39,51
Document the rationale for any antidepressant trial in Bipolar II, the mood stabilizer covering it, the planned duration, and the monitoring plan for switching, mixed features, and rapid cycling. The chart documentation is itself part of the treatment.37,39
| Intervention | Evidence base/Comparator | Benefits | Harms | Certainty | Notes |
|---|---|---|---|---|---|
| Quetiapine monotherapy (acute Bipolar II depression) | Multiple RCTs vs placebo (EMBOLDEN II and others) | Reduces depressive symptoms; effect size moderate | Sedation, weight gain, metabolic syndrome, orthostasis | moderate | First-line for acute Bipolar II depression in /ISBD and BAP guidelines |
| Lithium (maintenance) | RCTs and meta-analyses, larger evidence in Bipolar I | Reduces relapse and suicide risk | Tremor, polyuria, hypothyroidism, renal effects, narrow therapeutic window | moderate | Anti-suicide effect supported across mood disorders; level monitoring required |
| Lamotrigine (maintenance, depression prevention) | RCTs, especially CALABRESE maintenance program (Bipolar I data extrapolated) | Prevents depressive recurrence | Stevens-Johnson syndrome with rapid titration; slow titration mitigates risk | moderate | Weaker evidence for acute depression; stronger for prevention |
| Lurasidone (acute bipolar depression) | RCTs in Bipolar I; extrapolated to Bipolar II | Reduces depressive symptoms with low metabolic burden | , nausea; food requirement (350 kcal) for absorption | moderate | Common Bipolar II off-evidence use based on Bipolar I trials |
| Cariprazine (acute bipolar depression) | RCTs in Bipolar I depression | Reduces depressive symptoms | Akathisia, EPS, insomnia | moderate | Bipolar II evidence by extrapolation |
| Antidepressant monotherapy | Observational and RCT data | Limited or no benefit over placebo in bipolar depression in many analyses | Hypomanic switch, mixed features, rapid cycling, accelerated suicidality | low | Not recommended as monotherapy in current guidelines |
| Psychoeducation (adjunct) | RCTs vs treatment as usual | Reduces manic and hypomanic relapse; improves adherence | Time burden | moderate | Group format with structured curriculum has strongest evidence |
| CBT for bipolar disorder (adjunct) | RCTs and meta-analyses | Modest reduction of depressive symptoms; improved function | Time burden; effect attenuates over time | moderate | Adjunct to medication, not replacement |
| Interpersonal and social rhythm therapy | RCTs (STEP-BD) | Lengthens time to recurrence by stabilizing daily rhythms | Time burden | moderate | Particularly useful with sleep-wake disruption |
| ECT (severe, treatment-resistant, psychotic) | RCTs and meta-analyses across mood disorders | Robust antidepressant effect; effective in catatonia | Cognitive effects (transient memory), anesthesia risks | high | Reserved for severe/refractory presentations |
| rTMS in bipolar depression | RCTs and meta-analyses | Modest depressive symptom reduction | Headache, scalp discomfort, rare seizure | low | Smaller effect than in unipolar depression; switch risk low but non-zero |
The harms profile in Bipolar II is dominated by long-term medication exposure during a chronic illness, the specific risk of antidepressant-induced destabilization, and the consequences of delayed or missed diagnosis. The evidence base itself is a limitation: Bipolar II has been historically under-studied compared with Bipolar I.38-39
Common adverse effects
- Quetiapine: sedation, weight gain, metabolic syndrome, orthostasis, dry mouth.40,52
- Lithium: fine tremor, polyuria and polydipsia, weight gain, acne, hypothyroidism, mild cognitive blunting.28,42
- Lamotrigine: rash (most benign, some serious), headache, dizziness, insomnia.43
- Valproate: weight gain, alopecia, tremor, gastrointestinal upset, thrombocytopenia.28,53
- Lurasidone: akathisia, nausea, somnolence; weight and metabolic effects modest compared with other atypicals.41
Serious or rare adverse effects
- Lithium toxicity at levels above 1.5 mEq/L, with severe toxicity above 2.0 mEq/L: ataxia, dysarthria, confusion, seizures, arrhythmia, renal failure.28,42
- Lithium-associated chronic kidney disease and nephrogenic diabetes insipidus with .42
- Lamotrigine Stevens-Johnson syndrome and toxic epidermal necrolysis, particularly with rapid titration or co-administration of valproate without dose adjustment.43
- Valproate hepatotoxicity, pancreatitis, hyperammonemic encephalopathy, and major teratogenicity (neural tube defects, neurodevelopmental impairment).53-54
- Atypical antipsychotic metabolic syndrome, , and (rarely) .52
- Antidepressant-induced hypomanic switch, mixed features, rapid cycling, and treatment-emergent suicidality.37,39
Monitoring, withdrawal, and discontinuation
- Lithium requires periodic level monitoring, renal function, and TFTs; abrupt discontinuation increases the risk of recurrence and possibly attenuates the anti-suicide effect.28,42
- Lamotrigine requires slow re-titration if doses are missed for more than five days, because tolerance to the rash-mitigating titration is lost.43
- Atypical antipsychotic discontinuation can produce withdrawal dyskinesia and rebound symptoms; taper is preferred when possible.52
- Valproate is contraindicated in pregnancy and in women of childbearing potential without robust contraception.53-54
Limitations of the evidence base
- Most large bipolar depression RCTs were conducted in Bipolar I; Bipolar II-specific data are sparser, especially for maintenance.38-39
- Trial follow-up is typically short (8-12 weeks for acute studies, 6-24 months for maintenance), while the illness course spans decades.38-39
- Industry sponsorship and publication bias in the atypical antipsychotic literature warrant caution in interpreting effect sizes.39,55
- Heterogeneity in how hypomania is defined and ascertained across trials limits cross-study comparability.18,38
Pregnancy and postpartum
- Bipolar II carries elevated risk of episode recurrence in pregnancy and the postpartum period, and of postpartum psychosis.8,54
- Valproate is contraindicated in pregnancy because of teratogenicity and neurodevelopmental harm; it should be avoided in women of childbearing potential without robust contraception.53-54
- Lithium carries a small absolute risk of cardiac malformations (Ebstein anomaly), historically overestimated; risk and benefit must be discussed with the patient and weighed against the relapse risk of discontinuation.54,56
- Lamotrigine and quetiapine have comparatively reassuring reproductive safety data and are commonly used in pregnancy when a mood stabilizer is required.54
- Postpartum prophylaxis with the patient's previously effective mood stabilizer is recommended given the high recurrence risk in this window.8,54
Pediatric and adolescent
- Bipolar II is diagnosed in adolescents using DSM-5-TR criteria, but the boundary with severe mood dysregulation, ADHD, and emerging personality disorder is particularly difficult.57
- Family history is informative: a first-degree relative with bipolar disorder substantially raises pretest probability.5,57
- Antidepressant monotherapy in depressed youth with red-flag features should be approached cautiously given the switch and suicidality concerns.57
Older adults
- Late-onset hypomania (after age 50) should prompt evaluation for medical, neurologic, and substance-related causes before assuming primary Bipolar II.3,23
- Lithium clearance falls with age and renal function; dose reductions and closer level monitoring are required.28,42
- Polypharmacy and drug-drug interactions are a particular concern in older patients on lithium, valproate, or atypical antipsychotics.42,52
Comorbid substance use
- Alcohol and stimulant use are common and worsen course, suicide risk, and treatment response.3,15
- Integrated treatment of mood disorder and substance use disorder is preferred over sequential or parallel uncoordinated care.15
Comorbid borderline personality disorder
- Co-occurrence is common; clinicians should treat both rather than choosing between them, with mood stabilization and DBT skills as complementary strategies.24
Bipolar II is a chronic, recurrent illness with substantial functional impact and elevated mortality. With sustained, integrated treatment, many patients achieve symptomatic stability and meaningful function, but full and durable euthymia is uncommon.
Course
- Most patients experience recurrent depressive episodes throughout adulthood, with subsyndromal symptoms persisting between episodes in the majority.19
- Conversion to Bipolar I occurs in approximately 5-15% of patients over decades of follow-up.3,21
- Rapid cycling, mixed features, and comorbid anxiety, substance use, and personality disorders predict worse functional outcome.3,17,19
Mortality
- Suicide is the leading cause of premature mortality, with lifetime suicide risk of approximately 4-19% depending on the cohort and period of observation.6,17
- All-cause mortality is elevated, driven also by cardiovascular disease, substance use, and accidents.7,58
Functional outcome
- Vocational and interpersonal disability is common, with subsyndromal depression accounting for a disproportionate share of functional impairment.19
- Cognitive symptoms (attention, processing speed, executive function) persist between episodes in a substantial subset and contribute to functional outcome.59
Modifiable prognostic factors
- Medication adherence, structured psychosocial treatment, regular sleep-wake rhythm, abstinence from stimulants and heavy alcohol use, and active suicide-risk planning are the prognostic levers with the best supporting evidence.3,38-39,44
- Early diagnosis with avoidance of antidepressant monotherapy reduces iatrogenic destabilization and may improve long-term course.17,22,37
The acute psychiatric emergencies in Bipolar II are suicidality during depressed or mixed states, severe agitation in mixed hypomania, and (rarely) emergent mania converting the diagnosis to Bipolar I.
Suicidal ideation with plan or intent
- Immediate safety assessment, removal of access to lethal means (firearms, large medication supplies), and consideration of voluntary or involuntary hospitalization based on imminent risk and protective factors.6,27
- Contract-for-safety agreements have not been shown to prevent suicide and should not be relied upon as a primary intervention.27
- Lithium initiation or continuation is reasonable given the anti-suicide effect, with attention to safety in the context of overdose risk (smaller dispensed quantities).42
- ECT is appropriate for severe, treatment-resistant, or psychotic depression with active suicidality.48
Severe agitation in mixed hypomania
- Rapid taper or discontinuation of any contributing antidepressant.37,39
- Initiation or dose increase of an atypical antipsychotic, lithium, or valproate, with short-term benzodiazepine for agitation when needed.39
- Hospitalization for safety when the patient cannot be managed as an outpatient.39
Emergent manic episode
- A first manic episode reclassifies the patient as Bipolar I; treat as Bipolar I mania (atypical antipsychotic, lithium, or valproate; reduce or discontinue antidepressants; hospitalize if needed).16,39
Lithium toxicity
- Discontinue lithium, hydrate with isotonic saline, manage seizures and arrhythmia, and consult nephrology for hemodialysis when levels exceed 2.5 mEq/L or with severe symptoms or renal failure.28,42
Stevens-Johnson syndrome / toxic epidermal necrolysis
- Discontinue lamotrigine immediately, transfer to burn or specialist unit, supportive care; lifetime avoidance of lamotrigine after recovery.43
Neuroleptic malignant syndrome
- Discontinue offending antipsychotic, supportive care, dantrolene or bromocriptine in severe cases, intensive-care monitoring.52
Bipolar II is one of the more contested categories in contemporary psychiatry. The boundary with major depressive disorder, the validity of the four-day hypomania threshold, and the role of antidepressants remain unsettled.
- Is Bipolar II a distinct disorder, the depressive end of a bipolar spectrum, or a severity variant of recurrent depression with sub-threshold mood elevation? Each framing has implications for treatment thresholds and population estimates.3,19,60
- Should the four-day hypomania threshold be lowered to two days? Brief hypomanic episodes are common and clinically meaningful, but lowering the threshold risks over-pathologizing transient mood variation.18,60
- What is the proper role of antidepressants in Bipolar II? Some experts argue selected SSRI monotherapy is reasonable in stable patients without rapid cycling or mixed features; current consensus favors mood-stabilizer cover or avoidance.37,39,61
- How should rapid cycling and mixed features be conceptualized and operationalized? DSM-5-TR collapsed mixed features into a specifier, but the underlying neurobiology and treatment response patterns remain incompletely characterized.16-17
- What is the validity of "soft bipolar" or bipolar spectrum constructs that include hyperthymic temperament, brief hypomanic episodes, and antidepressant-induced hypomania? These constructs influence diagnostic practice but lack the regulatory or research consensus of DSM categories.19,60
- To what extent does undertreatment of Bipolar II depression reflect inadequate evidence, regulatory caution, or clinical inertia, and how should the field generate Bipolar II-specific evidence?38-39
- Bipolar II requires at least one hypomanic episode (≥4 days) and at least one major depressive episode; a single manic episode reclassifies the patient as Bipolar I.16
- Mood elevation lasting <4 days that otherwise meets hypomania criteria is coded as Other Specified Bipolar and Related Disorder, not Bipolar II.16
- Antidepressant-induced hypomania in DSM-5-TR can count toward the diagnosis of Bipolar II if it persists beyond the physiological effect of the medication.16,37
- DIG FAST and SIG E CAPS are the canonical mnemonics for hypomania/mania and major depression criteria, respectively.16
- First-line acute Bipolar II depression: quetiapine monotherapy.38-40
- Lithium has anti-suicide evidence across mood disorders and is recommended for maintenance; therapeutic range 0.6-1.2 mEq/L; toxicity above 1.5 mEq/L.28,42
- Lamotrigine prevents depressive recurrence and requires slow titration to mitigate Stevens-Johnson syndrome; avoid rapid escalation, especially with valproate co-administration.43
- Valproate is contraindicated in pregnancy and in women of childbearing potential without robust contraception.53-54
- Antidepressant monotherapy is not recommended in Bipolar II; if used, combine with a mood stabilizer or atypical antipsychotic, and monitor for switching, mixed features, and rapid cycling.37-39
- The strongest single risk factor for bipolar disorder is a first-degree relative with bipolar disorder, with heritability of approximately 60-85%.5
- ECT is highly effective for severe, treatment-resistant, or psychotic bipolar depression and for catatonia.48-49
References
- 1.Kraepelin E. Manic-Depressive Insanity and Paranoia. Edinburgh: E. & S. Livingstone; 1921.
- 2.Dunner DL, Gershon ES, Goodwin FK. Heritable factors in the severity of affective illness. Biol Psychiatry. 1976;11(1):31-42.
- 3.TextbookGoodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2nd ed. New York: Oxford University Press; 2007.
- 4.Merikangas KR, Jin R, He J-P, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241-251.
- 5.Smoller JW, Finn CT. Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet. 2003;123C(1):48-58.
- 6.Systematic reviewPlans L, Barrot C, Nieto E, et al. Association between completed suicide and bipolar disorder: a systematic review of the literature. J Affect Disord. 2019;242:111-122.
- 7.CohortHayes JF, Marston L, Walters K, et al. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014. Br J Psychiatry. 2017;211(3):175-181.
- 8.Systematic reviewWesseloo R, Kamperman AM, Munk-Olsen T, et al. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(2):117-127.
- 9.Sullivan PF, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet. 2012;13(8):537-551.
- 10.Stahl EA, Breen G, Forstner AJ, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 2019;51(5):793-803.
- 11.Phillips ML, Swartz HA. A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. Am J Psychiatry. 2014;171(8):829-843.
- 12.Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804-817.
- 13.Harvey AG. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry. 2008;165(7):820-829.
- 14.Bender RE, Alloy LB. Life stress and kindling in bipolar disorder: review of the evidence and integration with emerging biopsychosocial theories. Clin Psychol Rev. 2011;31(3):383-398.
- 15.Systematic reviewHunt GE, Malhi GS, Cleary M, Lai HMX, Sitharthan T. Comorbidity of bipolar and substance use disorders in national surveys of general populations, 1990-2015: systematic review and meta-analysis. J Affect Disord. 2016;206:321-330.
- 16.TextbookAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text Revision (DSM-5-TR). Washington, DC: American Psychiatric Association Publishing; 2022.
- 17.Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Primers. 2018;4:18008.
- 18.Angst J, Gamma A, Bowden CL, et al. Diagnostic criteria for bipolarity based on an international sample of 5,635 patients with DSM-IV major depressive episodes. Eur Arch Psychiatry Clin Neurosci. 2012;262(1):3-11.
- 19.Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003;73(1-2):123-131.
- 20.Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord. 2008;10(1 Pt 2):144-152.
- 21.Beesdo K, Höfler M, Leibenluft E, Lieb R, Bauer M, Pfennig A. Mood episodes and mood disorders: patterns of incidence and conversion in the first three decades of life. Bipolar Disord. 2009;11(6):637-649.
- 22.Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161-174.
- 23.Sajatovic M, Strejilevich SA, Gildengers AG, et al. A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord. 2015;17(7):689-704.
- 24.Zimmerman M, Morgan TA. The relationship between borderline personality disorder and bipolar disorder. Dialogues Clin Neurosci. 2013;15(2):155-169.
- 25.Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000;157(11):1873-1875.
- 26.Angst J, Adolfsson R, Benazzi F, et al. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord. 2005;88(2):217-233.
- 27.Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277.
- 28.Ng F, Mammen OK, Wilting I, et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009;11(6):559-595.
- 29.McIntyre RS, Berk M, Brietzke E, et al. Bipolar disorders. Lancet. 2020;396(10265):1841-1856.
- 30.Cassano GB, Rucci P, Frank E, et al. The mood spectrum in unipolar and bipolar disorder: arguments for a unitary approach. Am J Psychiatry. 2004;161(7):1264-1269.
- 31.Akiskal HS, Benazzi F. Optimizing the detection of bipolar II disorder in outpatient private practice: toward a systematization of clinical diagnostic wisdom. J Clin Psychiatry. 2005;66(7):914-921.
- 32.Hirschfeld RM. Differential diagnosis of bipolar disorder and major depressive disorder. J Affect Disord. 2014;169(Suppl 1):S12-S16.
- 33.Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672-1682.
- 34.Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol. 2004;24(6):599-606.
- 35.Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121(1-2):106-115.
- 36.Bauer M, Pfennig A. Epidemiology of bipolar disorders. Epilepsia. 2005;46(Suppl 4):8-13.
- 37.Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249-1262.
- 38.GuidelineYatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97-170.
- 39.TextbookGoodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495-553.
- 40.RCTSuppes T, Hirschfeld RM, Vieta E, Raines S, Paulsson B. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry. 2008;9(3):198-211.
- 41.RCTLoebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160-168.
- 42.Systematic reviewSeverus E, Taylor MJ, Sauer C, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord. 2014;2:15.
- 43.Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002;63(11):1012-1019.
- 44.Systematic reviewMiklowitz DJ, Efthimiou O, Furukawa TA, et al. Adjunctive psychotherapy for bipolar disorder: a systematic review and component network meta-analysis. JAMA Psychiatry. 2021;78(2):141-150.
- 45.RCTColom F, Vieta E, Sánchez-Moreno J, et al. Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry. 2009;194(3):260-265.
- 46.Frank E, Kupfer DJ, Thase ME, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry. 2005;62(9):996-1004.
- 47.RCTMiklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry. 2003;60(9):904-912.
- 48.Systematic reviewUK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799-808.
- 49.Systematic reviewBahji A, Hawken ER, Sepehry AA, Cabrera CA, Vazquez G. ECT beyond unipolar major depression: systematic review and meta-analysis of electroconvulsive therapy in bipolar depression. Acta Psychiatr Scand. 2019;139(3):214-226.
- 50.McGirr A, Karmani S, Arsappa R, et al. Clinical efficacy and safety of repetitive transcranial magnetic stimulation in acute bipolar depression. World Psychiatry. 2016;15(1):85-86.
- 51.Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73(1):81-86.
- 52.Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119-136.
- 53.CohortTomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530-538.
- 54.Khan SJ, Fersh ME, Ernst C, Klipstein K, Albertini ES, Lusskin SI. Bipolar disorder in pregnancy and postpartum: principles of management. Curr Psychiatry Rep. 2016;18(2):13.
- 55.RegulatoryTurner EH, Knoepflmacher D, Shapley L. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLoS Med. 2012;9(3):e1001189.
- 56.Patorno E, Huybrechts KF, Bateman BT, et al. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med. 2017;376(23):2245-2254.
- 57.Goldstein BI, Birmaher B, Carlson GA, et al. The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: knowledge to date and directions for future research. Bipolar Disord. 2017;19(7):524-543.
- 58.CohortCrump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 2013;70(9):931-939.
- 59.Systematic reviewBourne C, Aydemir Ö, Balanzá-Martínez V, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand. 2013;128(3):149-162.
- 60.Phelps J, Angst J, Katzow J, Sadler J. Validity and utility of bipolar spectrum models. Bipolar Disord. 2008;10(1 Pt 2):179-193.
- 61.Amsterdam JD, Lorenzo-Luaces L, Soeller I, Li SQ, Mao JJ, DeRubeis RJ. Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate. Br J Psychiatry. 2016;208(4):359-365.